Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 2Recruiting 1Available 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 3Expanded_access 1

Sponsor

Cancer Type

Genitourinary 4

Conditions

Non-Muscle Invasive Bladder Neoplasms 4Urologic Neoplasms 2Urinary Bladder Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma in Situ 2

Interventions

Gemcitabine 16Mitomycin 10Docetaxel 6BCG Vaccine 6erdafitinib 5durvalumab 4dodecyl maltoside 4Cystoscopy 4ALT-803 4Radiotherapy 25-aminolevulinic acid hexyl ester 2viscum album peptide 1tremelimumab 1toripalimab 1pirarubicin 1pemigatinib 1monalizumab 1hydroxycamptothecinum 1enfortumab vedotin 1chondroitin sulfate, sodium hyaluronate drug combination 1bicalutamide 1Watchful Waiting 1Urine Specimen Collection 1Transurethral Resection of Bladder 1Surveys and Questionnaires 1Patient Discharge 1Paclitaxel 1Nonsteroidal Anti-Androgens 1Mitozytrex 1Maintenance 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Non-Muscle Invasive Bladder Neoplasms × dodecyl maltoside × 1 year × Clear all
NCT07283835 2026-04-23

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Lepu Biopharma Co., Ltd.

Phase 2 Recruiting
16 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

CG Oncology, Inc.

Available
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT04452591 2026-03-16

BOND-003

CG Oncology, Inc.

Phase 3 Active not recruiting
190 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT06111235 2026-01-12

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

CG Oncology, Inc.

Phase 3 Active not recruiting
367 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡